Anika Therapeutics Stock Price and Value Analysis

Anika Therapeutics (NasdaqGS:ANIK) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

  • Ticker: ANIK (NasdaqGS)
  • Current price: $13.62
  • Sector: Unknown
  • Industry: Unknown

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Anika Therapeutics to reach your target.

Target type

ANIK Free Cash Flow Trend

Free Cash Flow trendline for ANIK
Free Cash Flow trendline for Anika Therapeutics

Hmm, we can't give any reliable projection for Anika Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the ANIK Numbers

ANIK Price
(Anika Therapeutics stock price per share)
$13.62
[?] PE Ratio versus Sector 122% higher than other Unknown stocks
[?] PE Ratio versus Industry 22% lower than other Unknown stocks
[?] Cash Yield 22.72%
[?] Free Cash Flow Jitter 100%

Insider Activity Summary

In the six months to 2026-11-18, 1 insider bought in 2 trades, about $41 thousand, and no insider sold shares.

The six months before that had 2 buys and 0 sales.

Recent Insider Activity

Open-market buys and sells reported by Anika Therapeutics's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-08-04 Fischetti Gary P Buy 1,000 $20.32
2026-08-03 Fischetti Gary P Buy 1,000 $20.75
2026-05-01 HENNEMAN JOHN B III Buy 5,000 $14.66
2026-04-30 Griffin Stephen D. (President and CEO) Buy 12,200 $12.29
2022-05-11 Colleran David (EVP, General Counsel, Corp Sec) Buy 1,500 $21.37
2022-03-14 Colleran David (EVP, General Counsel, Corp Sec) Buy 1,500 $26.65
2022-03-11 Levitz Michael L (EVP, CFO, Treasurer) Buy 4,000 $24.62
2022-03-11 Blanchard Cheryl R (President, CEO, Director) Buy 3,813 $25.81
2022-03-11 Blanchard Cheryl R (President, CEO, Director) Buy 4,287 $25.36
2022-03-11 Thompson Jeffery S Buy 2,000 $24.66

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 323,508 shares shorted. With 11,297,607 shares available for purchase and an average trading volume over the past 10 trading days of 143,520, it would take at least 2.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Cash Conversion

Over the 12 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $282.3 million against net income of $232.3 million, or 1.22 times. Net income was negative in 5 of the 17 years, and those years are left out of the ratio.

In 2025, net income was -$10.9 million and operating cash flow was $11.2 million, so no ratio is shown for that year.

In 2025, capital expenditures were $6.8 million, 61.0% of operating cash flow of $11.2 million, which leaves an estimated $4.4 million after capex. Across the 16 years with reported capex, it averaged 25.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 3.7 3.1 4.0 0.84
2010 4.3 7.9 2.8 1.82
2011 8.5 10.2 1.4 1.20
2012 11.8 10.5 1.5 0.90
2013 20.6 25.2 0.4 1.22
2014 38.3 40.0 1.6 1.04
2015 30.8 39.9 9.2 1.30
2016 32.5 24.4 14.0 0.75
2017 31.8 40.8 9.0 1.28
2018 18.7 34.9 4.7 1.87
2019 27.2 37.0 2.8 1.36
2020 -24.0 13.1 1.6 n/a
2021 4.1 8.4 5.1 2.03
2022 -14.9 4.4 7.5 n/a
2023 -82.7 -1.8 5.4 n/a
2024 -56.4 5.4 7.7 n/a
2025 -10.9 11.2 6.8 n/a

Revenue and Cash Margin

Revenue was $40.1 million in 2009 and $112.8 million in 2025, a compound annual growth rate of 6.7% over 16 years.

Revenue fell 5.9% from 2024 to 2025.

Our estimated free cash flow was $4.7 million in 2025, 4.1% of revenue. In 2009 the estimated margin was negative 2.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 40.1 -0.9 -2.2%
2010 55.6 4.5 8.1%
2011 64.8 7.5 11.5%
2012 71.4 8.1 11.4%
2013 75.1 23.1 30.8%
2014 105.6 38.4 36.4%
2015 93.0 37.1 39.9%
2016 103.4 19.1 18.5%
2017 113.4 34.0 30.0%
2018 105.6 27.2 25.8%
2019 114.6 29.1 25.4%
2020 130.5 6.6 5.1%
2021 147.8 3.8 2.5%
2022 113.8 0.1 0.1%
2023 120.8 -6.3 -5.2%
2024 119.9 -0.1 -0.1%
2025 112.8 4.7 4.1%

Balance Sheet

In 2025, cash and equivalents were $57.5 million against total liabilities of $46.8 million, or 122.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 24.6% of total assets in 2025, compared with 33.9% in 2010, a decrease of 9.3 percentage points.

Stockholders equity was $143.5 million in 2025, compared with $85.2 million in 2010, a rise of 68.4%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 4.2% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 128.9 28.2 43.7 85.2
2011 132.8 35.8 38.1 94.8
2012 142.1 44.1 33.1 108.9
2013 156.0 63.3 20.4 135.6
2014 192.8 100.2 14.7 178.1
2015 235.7 110.7 24.9 210.8
2016 240.2 104.3 17.5 222.8
2017 282.6 133.3 19.1 263.5
2018 279.0 89.0 15.4 263.6
2019 330.7 157.5 42.3 288.4
2020 365.6 95.8 93.2 272.4
2021 347.5 94.4 60.5 287.1
2022 349.1 86.3 63.6 285.6
2023 270.6 68.7 58.4 212.3
2024 202.7 55.6 48.8 154.0
2025 190.3 57.5 46.8 143.5

Price Versus Our Estimated Value

We do not estimate a fair value for Anika Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.

Only 14 of the 17 fiscal years under Anika Therapeutics's current filer show positive free cash flow.

Free cash flow is volatile from year to year, with a variability measure of 100%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

No dividend yield is recorded for Anika Therapeutics in our data.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 898437.

Each figure on this page comes from that filer.

Risks to This Analysis

  • Free cash flow was negative in 3 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ANIK

Does Anika Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ANIK

This example shows how we apply the Trendshare checklist to ANIK: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 13.62
    • Market cap: $182M
    • EPS: -0.03
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: 21.4%
    • Date checked: Nov 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.